385 related articles for article (PubMed ID: 19935741)
21. Relaxin abrogates genomic remodeling of the aged heart.
Romero G; Salama G
Vitam Horm; 2021; 115():419-448. PubMed ID: 33706957
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Clinical Candidate AZD5462, a Selective Oral Allosteric RXFP1 Agonist for Treatment of Heart Failure.
Granberg KL; Sakamaki S; Larsson N; Bergström F; Fuchigami R; Niwa Y; Ryberg E; Backmark A; Kato H; Miyazaki S; Iguchi K; Sakamoto T; Persson M; Idei A; Prieto Garcia L; Villar IC; Gradén H; Bergonzini G; Arvidsson T; Fujita T; Althage M; Ulander J; Kimura J; Yoneda H; Fjellström O; Mochida H; Lal M
J Med Chem; 2024 Mar; 67(6):4419-4441. PubMed ID: 38502782
[TBL] [Abstract][Full Text] [Related]
23. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.
Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A
Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514
[TBL] [Abstract][Full Text] [Related]
24. The actions of relaxin on the human cardiovascular system.
Sarwar M; Du XJ; Dschietzig TB; Summers RJ
Br J Pharmacol; 2017 May; 174(10):933-949. PubMed ID: 27239943
[TBL] [Abstract][Full Text] [Related]
25. Relaxin-2 for heart failure with preserved ejection fraction (HFpEF): Rationale for future clinical trials.
Dschietzig TB
Mol Cell Endocrinol; 2019 May; 487():54-58. PubMed ID: 30659842
[TBL] [Abstract][Full Text] [Related]
26. Cardioprotective actions of relaxin.
Martin B; Romero G; Salama G
Mol Cell Endocrinol; 2019 May; 487():45-53. PubMed ID: 30625345
[TBL] [Abstract][Full Text] [Related]
27. Relaxin reverses inflammatory and immune signals in aged hearts.
Martin B; Gabris-Weber BA; Reddy R; Romero G; Chattopadhyay A; Salama G
PLoS One; 2018; 13(1):e0190935. PubMed ID: 29346407
[TBL] [Abstract][Full Text] [Related]
28. Targeted biological therapies reach the heart: the case of serelaxin for heart failure.
Kumar VA; Wilson SS; Ayaz SI; Levy PD
Drugs Today (Barc); 2015 Oct; 51(10):591-7. PubMed ID: 26583301
[TBL] [Abstract][Full Text] [Related]
29. Receptor-independent modulation of TGF-β-induced pro-fibrotic pathways by relaxin-2 in human primary tubular epithelial cells.
Grampp S; Goppelt-Struebe M
Cell Tissue Res; 2018 Dec; 374(3):619-627. PubMed ID: 30078103
[TBL] [Abstract][Full Text] [Related]
30. Relaxin: antifibrotic properties and effects in models of disease.
Samuel CS
Clin Med Res; 2005 Nov; 3(4):241-9. PubMed ID: 16303890
[TBL] [Abstract][Full Text] [Related]
31. Relaxin in vascular physiology and pathophysiology: possible implications in ischemic brain disease.
Nistri S; Bani D
Curr Neurovasc Res; 2005 Jul; 2(3):225-3. PubMed ID: 16181116
[TBL] [Abstract][Full Text] [Related]
32. Editorial to the mini-review series on relaxin, related peptides and receptors?
Klonisch T
Mol Cell Endocrinol; 2019 May; 487():1. PubMed ID: 30831203
[No Abstract] [Full Text] [Related]
33. Studies of the molecular mechanisms of action of relaxin on the adenylyl cyclase signaling system using synthetic peptides derived from the LGR7 relaxin receptor.
Shpakov AO; Gur'yanov IA; Kuznetsova LA; Plesneva SA; Shpakova EA; Vlasov GP; Pertseva MN
Neurosci Behav Physiol; 2007 Sep; 37(7):705-14. PubMed ID: 17763990
[TBL] [Abstract][Full Text] [Related]
34. Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity.
Pini A; Shemesh R; Samuel CS; Bathgate RA; Zauberman A; Hermesh C; Wool A; Bani D; Rotman G
J Pharmacol Exp Ther; 2010 Dec; 335(3):589-99. PubMed ID: 20826567
[TBL] [Abstract][Full Text] [Related]
35. Relaxin in cardiovascular and renal disease.
Samuel CS; Hewitson TD
Kidney Int; 2006 May; 69(9):1498-502. PubMed ID: 16672919
[TBL] [Abstract][Full Text] [Related]
36. The actions of relaxin family peptides on signal transduction pathways activated by the relaxin family peptide receptor RXFP4.
Ang SY; Hutchinson DS; Evans BA; Hossain MA; Patil N; Bathgate RA; Kocan M; Summers RJ
Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):105-111. PubMed ID: 27888281
[TBL] [Abstract][Full Text] [Related]
37. [Study of molecular mechanisms of the relaxin action on adenylyl cyclase signaling system using synthetic peptides derived from the relaxin receptor LGR7].
Shpakov AO; Gur'ianov IA; Kuznetsova LA; Plesneva SA; Shpakova EA; Vlasov GP; Pertsev MN
Ross Fiziol Zh Im I M Sechenova; 2006 May; 92(5):521-35. PubMed ID: 16869281
[TBL] [Abstract][Full Text] [Related]
38. Physiological or pathological--a role for relaxin in the cardiovascular system?
Samuel CS; Parry LJ; Summers RJ
Curr Opin Pharmacol; 2003 Apr; 3(2):152-8. PubMed ID: 12681237
[TBL] [Abstract][Full Text] [Related]
39. Serelaxin a novel treatment for acute heart failure.
Castrini AI; Carubelli V; Lazzarini V; Bonadei I; Lombardi C; Metra M
Expert Rev Clin Pharmacol; 2015; 8(5):549-57. PubMed ID: 26294074
[TBL] [Abstract][Full Text] [Related]
40. Serelaxin as a novel therapeutic opposing fibrosis and contraction in lung diseases.
Lam M; Royce SG; Samuel CS; Bourke JE
Pharmacol Ther; 2018 Jul; 187():61-70. PubMed ID: 29447958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
